MA44309A - Oligonucléotides antisens il-34 et leurs procédés d'utilisation - Google Patents

Oligonucléotides antisens il-34 et leurs procédés d'utilisation

Info

Publication number
MA44309A
MA44309A MA044309A MA44309A MA44309A MA 44309 A MA44309 A MA 44309A MA 044309 A MA044309 A MA 044309A MA 44309 A MA44309 A MA 44309A MA 44309 A MA44309 A MA 44309A
Authority
MA
Morocco
Prior art keywords
fibrosis
inflammatory diseases
antisens
oligonucleotides
use methods
Prior art date
Application number
MA044309A
Other languages
English (en)
French (fr)
Inventor
Salvatore Bellinvia
Marie Mcnulty
Francesca Viti
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MA44309A publication Critical patent/MA44309A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044309A 2015-11-25 2016-11-25 Oligonucléotides antisens il-34 et leurs procédés d'utilisation MA44309A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260076P 2015-11-25 2015-11-25

Publications (1)

Publication Number Publication Date
MA44309A true MA44309A (fr) 2018-10-03

Family

ID=57471829

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044309A MA44309A (fr) 2015-11-25 2016-11-25 Oligonucléotides antisens il-34 et leurs procédés d'utilisation

Country Status (13)

Country Link
US (1) US20180338992A1 (https=)
EP (1) EP3380615B1 (https=)
JP (2) JP2018535681A (https=)
KR (1) KR20180084956A (https=)
CN (1) CN108473989A (https=)
AU (1) AU2016360956A1 (https=)
BR (1) BR112018010736A2 (https=)
CA (1) CA3005932A1 (https=)
ES (1) ES2861516T3 (https=)
MA (1) MA44309A (https=)
MX (1) MX2018006445A (https=)
PT (1) PT3380615T (https=)
WO (1) WO2017089555A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3420082A4 (en) * 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
AU2020384935A1 (en) * 2019-11-15 2022-06-09 Nogra Pharma Limited IL-34 antisense agents and methods of using same
AU2022276078A1 (en) 2021-05-17 2024-01-04 Nogra Pharma Limited Il-34 antisense agents and methods of using same
WO2022243299A1 (en) * 2021-05-17 2022-11-24 Nogra Pharma Limited Il-34 antisense agents and methods of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2242854A4 (en) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc COMPOUNDS AND USES THEREOF
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
GB0910833D0 (en) * 2009-06-23 2009-08-05 Univ Edinburgh Avian genes
US20130028889A1 (en) * 2010-02-04 2013-01-31 Ico Therapeutics Inc. Dosing regimens for treating and preventing ocular disorders using c-raf antisense
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
DK2734547T3 (en) * 2011-07-18 2017-04-03 Univ Melbourne USE OF C-FMS ANTIBODIES
CN107759690A (zh) * 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
KR20150104275A (ko) * 2014-03-05 2015-09-15 울산대학교 산학협력단 비만 관련 질환의 진단과 치료를 위한 il-34의 용도
CA2954791C (en) * 2014-07-14 2025-11-18 The Regents Of The University Of California CRISPR/CAS TRANSCRIPTIONAL MODULATION

Also Published As

Publication number Publication date
CA3005932A1 (en) 2017-06-01
EP3380615A1 (en) 2018-10-03
AU2016360956A1 (en) 2018-06-07
MX2018006445A (es) 2018-08-01
ES2861516T3 (es) 2021-10-06
PT3380615T (pt) 2021-04-01
KR20180084956A (ko) 2018-07-25
JP2021106625A (ja) 2021-07-29
EP3380615B1 (en) 2021-01-06
JP2018535681A (ja) 2018-12-06
BR112018010736A2 (pt) 2018-11-27
CN108473989A (zh) 2018-08-31
WO2017089555A1 (en) 2017-06-01
US20180338992A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
GB2419882B (en) Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
BR112021024463A2 (pt) Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas
MX2024005653A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
MA43347B1 (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
MX385869B (es) Agentes de iarn modificados.
MA33488B1 (fr) Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
MA44309A (fr) Oligonucléotides antisens il-34 et leurs procédés d'utilisation
WO2017019660A8 (en) Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
PE20211393A1 (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO
EP1904111A4 (en) COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA
WO2007027761A3 (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
MX2023008408A (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
RU2014101547A (ru) Апоптоз-индуцирующее средство
EA201391468A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
WO2019217397A3 (en) Compositions and methods for improving strand biased
Tehrani et al. Competing endogenous RNAs (CeRNAs): novel network in neurological disorders
MA39145A1 (fr) Dérivés de pipérazine ayant une activité multimode contre la douleur
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA44836A (fr) Procédés de traitement du syndrome polykystique des reins
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
BR112022009254A2 (pt) Agentes antissenso il-34 e métodos de usar os mesmos
BR112021016907A2 (pt) Oligonucleotídeos de interferência com proteína de retardo mental do x frágil e métodos de sua utilização
WO2016145362A3 (en) Inhibitors of dek protein and related methods